This article examines consumers’ attitudes toward Direct-to-Consumer (DTC) advertising of prescription drugs that are influenced by the use different types of DTC ads and product involvement. Our findings suggest that product involvement and the type of DTC ad are significant predictors of consumers’ attitudinal responses toward DTC advertising. High involvement consumers have more favorable attitudes toward the drug's price, DTC ad and brand name, and a higher intention to ask a doctor about the advertised drug than low involvement consumers. In contrast to Informational and Reminder DTC ads, Persuasive ads have more favorable effects on consumers’ reactions to DTC prescription drug advertising.
Get full access to this article
View all access options for this article.
References
1.
AlpersteinN. M. & PeyrotM. (1993). Consumer Awareness of Prescription Drug Advertising. Journal of Advertising Research, 33(4), 50–56.
2.
America's Most Admired Companies. (2005, April 18). Fortune, 66–70, 85–97.
3.
America's Most Admired Companies. (2006, April 17). Fortune.
4.
A National Survey of Consumer Reactions to Direct-to-Consumer Advertising (2000). Preventive Magazine.
5.
BoltonL. E., WarlopL., & AlbaJ. W. (2003). Consumer Perception of Price (Un) Fairness. Journal of Consumer Research, 29, 474–491.
6.
BrownS. P. & StaymanD. M. (1992). Antecedents and Consequences of Attitude Toward the Ad: A Meta-analysis. Journal of Consumer Research, 19(1), 34–51.
7.
CalfeeJ. E. (2002). Public Policy Issues in Direct-to-Consumer Advertising of Prescription Drugs. Journal of Public Policy & Marketing, 21, 174–193.
8.
CelsiR. L. & OlsonJ. C. (1988). The Role of Involvement in Attention and in Comprehension Processes. Journal of Consumer Research, 15, 210–224.
9.
CrispR. (1987). Persuasive Advertising, Autonomy, and the Creation of Desire. Journal of Business Ethics, 6(5), 413–418.
10.
CutlerB. D., ThomasE. G., & RaoS.R. (2000). Informational/Transformational Advertising: Differences in Usages Across Media Types, Product Categories, and National Cultures. Journal of International Consumer Marketing, 12(3), 69–83.
11.
DukesD. E. (2001). What You Should Know about Direct-to-Consumer Advertising of Prescription Drugs. Defense Counsel Journal, 68(1), 36–49.
12.
FarrisP. W. & ReibsteinD. J. (1979). How prices, ad expenditures, and profits are linked. Harvard Business Review, 57(6), 173–184.
13.
FarrisP. W. & AlbionM. S. (1980). The Impact of Advertising on the Price of Consumer Products. Journal of Marketing, 44(3), 17–35.
14.
FinlaysonG. & MullnerR. (2005). Direct-to-consumer advertising of prescription drugs: help or hindrance to the public's health?. Journal of Consumer Marketing, 22(7), 429–431.
15.
Food and Drug Administration (1999). Attitudes and Behaviors Associated with Direct-to-Consumer Promotion of Prescription Drugs. Retrieved June 16, 2007, from: www.fda.gov/cder/ddmac/research.htm.
16.
GardnerM. P. (1985). Does Attitude toward the Ad Affect Brand Attitude under a Brand Evaluation Set?. Journal of Marketing Research, 22(2), 192–198.
17.
GardnerM. P., MitchellA. A., & RussoJ. E. (1985). Low Involvement Strategies for Processing Advertisements. Journal of Advertising, 14(2), 4–12.
18.
GaskiJ. F. & EtzelM. J. (1986). The Index of Consumer Sentiment Toward Marketing. Journal of Marketing, 50, 71–81.
19.
GreyserS. A. & ReeceB. B. (1971). Businessman Look Hard at Advertising. Harvard Business Review, 49, 18–26, 157–165.
20.
HerrickD. M. (2004). Shopping for Drugs: 2004. National Center for Policy Analysis, Policy Report No. 270, October 11.
21.
HerzensteinM., MisraS., & PosavacS. (2005). How Consumers' Attitudes Toward Direct-to-Consumer Advertising of Prescription Drugs Influence Ad Effectiveness, and Consumer and Physician Behavior. Marketing Letter, 15(4), 201–212.
22.
HolmerA. F. (1999). Direct-to-Consumer Prescription Drug Advertising Builds Bridges between Patients and Physicians. Journal of the American Medical Association, 281(4), 380–382.
23.
HomerP. M. (1995). Ad Size as an Indicator of Perceived Advertising Costs and Effort: The Effect of Memory and Perceptions. Journal of Advertising, 24(4), 1–12.
24.
HuhJ. & BeckerL. B. (2005). Direct-to-consumer Prescription Drug Advertising: Understanding Its Consequences. International Journal of Advertising, 24(4), 441–466.
25.
HuntS. D. (2001). Informational vs. Persuasive Advertising: An Appraisal. Journal of Advertising, 5(3), 5–8.
26.
IMS Health (2000). US Leading Products by DTC Spend. January-December.
27.
IMS Health. (2006). Total U.S. Promotional Spend by Type, 2005. Top-Line Industry Data, May.
28.
IvanovicA. & CollinP. H. (2003). Dictionary of Marketing, Third Edition, Bloomsbury Publishing Plc, London.
29.
Kaiser Family Foundation (2002). Trends and Indicators in the Changing Health Care Marketplace. Chartbook (May).
30.
Kaiser Family Foundation (2002). Seniors and Prescription Drugs: Finding from a 2001 Survey of Seniors in Eight States. July 31.
31.
Kaiser Family Foundation (2003). Impact of Direct-to-consumer Advertising on Prescription Drug Spending. The Henry J. Kaiser Foundation, Washington, DC, 1–11.
32.
Kaiser Family Foundation (2004). Prescription Drug Trends. The Henry J. Kaiser Foundation, October, 1–2.
33.
KirmaniA. (1990). The Effects of Perceived Advertising Costs on Brand Perceptions. Journal of Consumer Research, 17, 160–171.
LaczniakR. N., MuehlingD. D. & GrossbartS. (1989). Manipulating Message Involvement in Advertising Research. Journal of Advertising, 18(2), 28–38.
36.
LaczniakR. N., KempfD. S. & MuehlingD. D. (1999). Advertising Message Involvement: The Role of Enduring and Situational Factors. Journal of Current Issues and Research in Advertising, 21(1), 51–61.
37.
LeeB., SalmonC. T., & PaekH. (2007). The Effects of Information Sources on Consumer Reactions to Direct-to-Consumer (DTC) Prescription Drug Advertising: A Consumer Socialization Approach. Journal of Advertising, 36(1), 107–119.
38.
MacKenzieS. B., LutzR. J., & BelchG. E. (1986). The Role of Attitude Toward the Ad as a Mediator of Advertising Effectiveness: A Test of Competing Explanations. Journal of Marketing Research, 23(2), 130–143.
39.
MarquezF. T. (1977). Advertising Content: Persuasion, Information or Intimidation?. Journalism Quarterly, 54, 482–491.
40.
McGrathJ. M. & MahoodC. (2004). The Impact of Arousing Programming and Product Involvement on Advertising Effectiveness. Journal of Current Issues & Research in Advertising, 26(2), 41–52.
41.
McGuireW. J. (1978). An Information Processing Model of Advertising Effectiveness. Behavioral and Management Science in Marketing, eds. DavisHarry L. and SilkAlvin H.. New York: Ronald Press, 156–80.
42.
MehtaA. & PurvisS. C. (2003). Consumer Response to Print Prescription Drug Advertising. Journal of Advertising Research, 43(2), 194–206.
43.
MitchellA. A. & OlsonJ. C. (1981). Are Product Attribute Beliefs the Only Mediator of Advertising Effects on Brand Attitude?. Journal of Marketing Research, 18(3), 318–332.
MoriartyS. E. (1987). A Content Analysis of Visuals Used in Print Media Advertising. Journalism Quarterly, 64(1), 550–554.
46.
NIHCM Foundation Research Brief, September 2000.
47.
PeyrotM., AlpersteinN. M., DorenD.V., & PoliL.G. (1998). Direct-to-Consumer Ads Can Influence Behavior: Advertising increases consumer knowledge and prescription drug requests. Marketing Health Services, 18(2), 26–32.
48.
PetroshiusS. M., TitusP. A., & HatchK. J. (1995). Physician Attitudes Toward Pharmaceutical Drug Advertising. Journal of Advertising Research, 35, 41–51.
49.
PettyR. E. & CacioppoJ. T. (1979). Issue involvement can increase or decrease persuasion by enhancing message - relevant cognitive responses. Journal of Personality and Social Psychology, 37(10), 1915–1926.
50.
PettyR. E. & CacioppoJ. T. (1986a). Communication and Persuasion: Central and Peripheral Routes to Attitude Change.Springer-Verlag, New York, NY, 123–205.
51.
PettyR. E. & CacioppoJ. T. (1986b). Elaboration Likelihood Model of Persuasion. in BerkowitzL. (Ed.), Advances in Experimental Social Psychology, Academic Press, New York, NY.
52.
PhelpsJ. & ThorsonE. (1991). Brand Familiarity and Product Involvement Effects on the Attitude Toward an Ad-Brand Attitude Relationship. Advances in Consumer Research, 18(1), 202–209.
53.
PutoC. P. & WellsW. D. (1984). Informational and Transformational Advertising: The Differential Effects of Time. Advances in Consumer Research, 11, 638–643.
54.
PutrevuS. & LordK. R. (1994). Comparative and Noncomparative Advertising: Attitudinal Effects Under Cognitive and Affective Involvement Conditions. Journal of Advertising, 23, 77–90.
RelmanA. S. & AngellM. (2002). How the drug industry distorts medicine and politics: America's Other Drug Problem. The New Republic, 227(25), 27–41.
57.
SearingA. (2003). Prescription Drug Pricing: The Consumer Perspective. North Carolina Medical Journal, 64 (6), 300–302.
58.
SteinerR. L. (1973). Does Advertising Lower Consumer Prices?. Journal of Marketing, 37(4), 19–26.
59.
SteinerR. L. (1978). A Dual Stage Approach to the Effects of Brand Advertising on Competition and Price. in Marketing and the Public Interest, CadyJohn F., ed., Boston: Marketing Science Institute Report No. 78–105, 127–150.
60.
WeissmanJ. S., BlumenthalD., SilkA. J., ZapertK., NewmanM., & LeitmanR. (2003). Consumers' Reports On The Health Effects Of Direct-To-Consumer Drug Advertising. Health Affairs, Jan-Jun; Suppl Web Exclusives:W3–82–95.
61.
WestD. (1999). Mixing it Up in the Media. Pharmaceutical Executive DTC Times Supplement, 2(9), 6.
62.
WilliamsJ. R. & HenselP. J. (1995). Direct-to-Consumer Advertising of Prescription Drugs. Journal of Health Care Marketing, 15(1), 35–41.
63.
ZaichkowskyJ. L. (1985). Measuring the Involvement Construct. Journal of Consumer Research, 12(3), 341–352.
64.
ZauggA. M. (2005). IMS Health Report: Pressure Zone. Medical Marketing and Media, May, 36–50.
